PureTech Health PLC Notice of Results (5158F)
March 10 2020 - 3:00AM
UK Regulatory
TIDMPRTC
RNS Number : 5158F
PureTech Health PLC
10 March 2020
10 March 2020
PureTech Health plc
Notice of Results
PureTech Health plc (LSE: PRTC) ("PureTech," or the "Company")
plans to announce its financial results for the year ended 31
December 2019 on Thursday, 9 April 2020.
A presentation and conference call for analysts will take place
at 2:00pm BST / 9:00am EDT, and a webcast of the presentation will
be available on the Company's website at
http://puretechhealth.com/investors under the Reports and
Presentations tab.
PureTech also confirms that the global outbreak of COVID-19 has
not adversely affected the Company's business of addressing major
diseases through its leadership in immunology and the
Brain-Immune-Gut (BIG) Axis. The Company has a very strong cash
position and is advancing the business in accordance with its
previously announced strategy and timelines while continuing to
monitor the situation.
About PureTech Health
PureTech is a clinical stage biotherapeutics company dedicated
to discovering, developing and commercialising highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's affiliates, is
comprised of 23 product candidates and one product that has been
cleared by the US Food and Drug Administration (FDA). All of the
underlying programmes and platforms that resulted in this pipeline
of product candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the Company's unique insights into the biology of the
brain, immune and gut, or BIG, systems and the interface between
those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORBCGDXUXGDGGC
(END) Dow Jones Newswires
March 10, 2020 03:00 ET (07:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024